






Supplementary information to:

THE IMPACT OF PHYSICAL ACTIVITY ON CARDIOVASCULAR MORTALITY IN THE GENERAL POPULATION

Tetsuya Takahashi, MD¹ , Tetsu Watanabe, MD, PhD¹ , Harutoshi Tamura, MD, PhD¹, Satoshi Nishiyama, MD, PhD¹, Hiroki Takahashi, MD, PhD¹, Takanori Arimoto, MD, PhD¹, Tetsuro Shishido, MD, PhD¹, Kazunobu Ichikawa, MD, PhD¹, Sumito Inoue, MD, PhD¹, Tsuneo Konta, MD, PhD¹ , Yoshiyuki Ueno, MD, PhD² , Takeo Kato, MD, PhD², Takamasa Kayama, MD, PhD², Masafumi Watanabe, MD, PhD¹ 

¹ Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, Yamagata, Japan

² Global Center of Excellence Program Study Group, Yamagata University School of Medicine, Yamagata, Japan

* **Corresponding author:** Tetsu Watanabe, MD, PhD, Department of Cardiology, Pulmonology, and Nephrology, Yamagata University School of Medicine, 2-2-2 Iida-Nishi, Yamagata, 990-9585, Japan, Phone: +81-23-628-5302; Fax: +81-23-628-5305; E-mail: tewatana@med.id.yamagata-u.ac.jp

<http://dx.doi.org/10.17179/excli2021-3818>

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>).

Supplementary Table 1: Clinical characteristics of subjects according to previous CVD

| | Previous CVD (-) (n = 1723) | Previous CVD (+) (n = 103) | P value |
|--|--|---------------------------------------|----------------|
| Age, years | 61.8 ± 10.3 | 64.7 ± 9.4 | 0.0068 |
| Male, n (%) | 745 (43) | 55 (53) | 0.0445 |
| Obesity, n (%) | 481 (28) | 23 (22) | 0.2085 |
| Smoking, n (%) | 529 (31) | 42 (41) | 0.0360 |
| Hypertension, n (%) | 923 (54) | 63 (61) | 0.1309 |
| Diabetes mellitus, n (%) | 125 (7) | 3 (3) | 0.0610 |
| Hyperlipidemia, n (%) | 820 (48) | 50 (49) | 0.8509 |
| CKD, n (%) | 145 (8) | 8 (8) | 0.8156 |
| MetS, n (%) | 255 (19) | 11 (11) | 0.2313 |
| Insulin resistance, n (%) | 177 (10) | 8 (8) | 0.3962 |
| LVH, n (%) | 70 (4) | 7 (7) | 0.2141 |
| AF, n (%) | 24 (1) | 3 (3) | 0.2686 |
| SBP, mmHg | 134 ± 16 | 135 ± 18 | 0.4981 |
| DBP, mmHg | 80 ± 10 | 80 ± 10 | 0.5053 |
| HbA1c, % | 5.3 ± 0.6 | 5.2 ± 0.4 | 0.2200 |
| FBG, mg/dL | 91.7 ± 24.1 | 87.4 ± 24.4 | 0.0843 |
| Hb, g/dL | 13.8 ± 1.4 | 14.0 ± 1.5 | 0.3866 |
| eGFR, ml/min/1.73m² | 80.7 ± 16.9 | 78.9 ± 16.8 | 0.2788 |
| BNP, pg/ml (IQR) | 18.4 (9.9-32.2) | 25.7 (11.8-49.0) | 0.0028 |
| Framingham risk score | 13.5 ± 5.2 | 15.0 ± 4.6 | 0.0046 |
| Physical activity (low/mild/moderate high), n (%) | 434(25)/437(25)/420(24)/432(25) | 24(23)/24(23)/33(32)/22(21) | 0.3932 |

Data are presented as mean ± standard deviation or % unless otherwise indicated; IQR, interquartile range; CV, cardiovascular; CVD, cardiovascular disease; CKD, chronic kidney disease; MetS, metabolic syndrome; LVH, left ventricular hypertrophy; AF, atrial fibrillation; BP, blood pressure; HbA1c, glycosylated hemoglobin A1c; FBG, fasting blood glucose; Hb, hemoglobin; eGFR, estimated glomerular filtration rate; BNP, brain natriuretic peptide